Latest News

Catalyst Pharmaceuticals (CPRX) has drawn fresh attention after Forbes ranked it 11th on the 2026 list of America’s Most Successful Small-Cap Companies, citing its sales growth and recent financial performance. See our latest analysis for Catalyst Pharmaceuticals. The recent Forbes recognition comes as the 90 day share price return sits at 11.59%, while the 1 year total shareholder return of 3.65% contrasts with a very large 5 year total shareholder return, suggesting momentum has cooled...

In recent days, Stanley Black & Decker has faced a mix of developments, including a federal safety lawsuit, a new Chief Global Supply Chain Officer appointment, and anticipation of its past fourth-quarter 2025 earnings release after earlier reporting flat quarterly revenue with an adjusted EPS beat and ongoing DEWALT brand strength. At the same time, a policy-driven rotation into defensive industrials amid calls for a very large US$1.50 trillion 2027 defense budget has highlighted Stanley...

In recent months, Sally Beauty Holdings reported solid quarterly results that underscored its role as a key supplier to DIY hair color customers and small salon professionals, while maintaining a relatively flat store footprint and same-store sales performance. At the same time, the company’s use of social media trends, e-commerce, and cost management to stay relevant with loyal customer segments has renewed attention on how its value-focused model can hold up despite limited physical...

AGCO recently announced that its Fendt, Massey Ferguson, and PTx brands earned seven 2026 AE50 awards from the American Society of Agricultural and Biological Engineers, recognizing engineering innovation and market impact across tractors, balers, autonomy kits, precision sensors, and nutrient analysis technologies. These multiple awards highlight AGCO’s farmer-focused innovation in autonomy-ready machinery and precision agritech, underscoring its role in shaping next‑generation agricultural...

Earlier this week, Raymond James reaffirmed its Buy rating on TowneBank, citing the bank’s latest earnings release showing revenue growth compared with the prior year. The combination of a supportive analyst stance and improving top-line performance has sharpened investor focus on how TowneBank’s business is evolving. Next, we will examine how Raymond James’ reiterated Buy rating and TowneBank’s revenue growth shape the company’s broader investment narrative. Outshine the giants: these 28...

On 7 January 2026, Walker & Dunlop and Pretium announced a US$250 million joint venture, Walker & Dunlop Affordable Bridge Capital, to provide short-term first-mortgage bridge loans for multifamily properties transitioning into long-term affordable housing programs such as LIHTC, Section 8, and tax-exempt bonds. This move highlights Walker & Dunlop’s growing focus on affordable housing finance, using flexible bridge lending to support projects seeking Agency and HUD takeout solutions. Next,...

Integer Holdings (ITGR) cut its full year 2025 sales guidance and flagged slower 2026 sales growth in electrophysiology products, a shift that is now paired with multiple securities class action lawsuits challenging its prior growth messaging. See our latest analysis for Integer Holdings. The share price reaction to the guidance cut and lawsuit headlines has been sharp over the past few months. However, the recent 7 day share price return of 9.81% and 30 day share price return of 17.18%...

Why Apogee’s latest asthma data has investors watching the stock Apogee Therapeutics (APGE) is back in focus after releasing interim Phase 1b data for its asthma candidate zumilokibart, along with a packed 2026 clinical timetable that could influence how investors evaluate the company’s pipeline. See our latest analysis for Apogee Therapeutics. At a latest share price of $77.99, Apogee’s 90 day share price return of 48.64% and 1 year total shareholder return of 89.99% suggest momentum has...

Grindr Inc. recently elevated Tristan Pineiro to Chief Marketing Officer and Zac Katz to Chief Legal Officer, General Counsel, and Head of Global Affairs, formalizing leadership over brand, advertising accessibility, legal, privacy, government affairs, and social impact initiatives. The appointments consolidate oversight of Grindr’s Global Gayborhood branding and Grindr for Equality advocacy under executives already shaping marketing-led growth, AI-related governance, and global LGBTQ+...

S&T Bancorp (STBA) is back on investors’ radar after its latest quarterly report, where revenue was higher than a year earlier and topped analyst expectations, while management highlighted strong return metrics. See our latest analysis for S&T Bancorp. At a share price of US$39.92, S&T Bancorp has seen a 12.48% 90 day share price return, while its 1 year total shareholder return of 16.76% and 5 year total shareholder return of 70.69% point to momentum that has been building rather than...

In recent days, Akamai Technologies has drawn heightened attention as multiple research firms reaffirmed or upgraded their views, citing the company’s global cloud, security, and content delivery platform as a core enabler of digital experiences across nearly 130 countries. This wave of analyst optimism, tied to expectations for continued growth in areas like cloud infrastructure and security, has sharpened the market’s focus on how effectively Akamai can translate its extensive network...

Appen (ASX:APX) is back in focus after quarterly results showed revenue ahead of estimates, putting its AI data services in the spotlight, while ongoing losses and margin pressure keep earnings quality under close watch. See our latest analysis for Appen. The quarterly revenue beat comes after a strong recent run in the shares, with the latest 30 day share price return of 39.13% and a 90 day share price return of 12.28%, in contrast to a 1 year total shareholder return decline of 65.47%. This...

BofA Securities analyst Pavan Patel recently initiated coverage on Amphastar Pharmaceuticals with a hold rating while the company’s CEO and CFO previously presented at the J.P. Morgan 2026 Healthcare Conference, highlighting its focus on generic and proprietary injectable, inhalation, and intranasal products. Together, the fresh analyst coverage and high-profile conference appearance have brought Amphastar’s pipeline investments and capacity expansion efforts into sharper focus for...

In early January 2026, Regencell Bioscience Holdings saw intense trading swings amid ongoing scrutiny from a U.S. Department of Justice investigation into activity in its shares and disclosures highlighting uncertainty about its ability to continue as a going concern. The combination of unusual trading volumes, momentum-driven moves, and the absence of fresh operational updates has left the stock highly sensitive to sentiment and regulatory headlines. We’ll now examine how this mix of DOJ...

WEX (WEX) has drawn attention after its shares closed at $161.88, with recent returns over the past week, month, and past 3 months giving investors fresh context for its current valuation. See our latest analysis for WEX. The recent 1-day share price return of 1.83% and 7-day share price return of 9.09% come after a year where the 1-year total shareholder return declined 4.96%. This suggests short term momentum is picking up while longer term returns have been weaker. If WEX has you...

Harbour’s appointment as operator of the Zama project in Mexico marks an important shift for Talos Energy (TALO), given Zama’s role in the company’s portfolio and in its future development plans. See our latest analysis for Talos Energy. The Zama operatorship shift comes at a time when Talos Energy’s share price has retreated in the short term, with a 30 day share price return decline of 9.21%, even as the 90 day share price return of 19.65% and 1 year total shareholder return of 1.88% point...

Recently, Renault’s shares moved lower after management comments raised concerns about the company’s profit margins and overall profitability outlook. This reaction highlights how sensitive investors are to any sign that Renault’s margin recovery story may be more challenging than previously thought. We’ll now examine how these renewed worries about Renault’s profit margins may influence the company’s existing investment narrative and risk profile. Trump has pledged to "unleash" American oil...

In early January 2026, Arcellx, Inc. filed a US$209.19 million shelf registration for 3,208,367 common shares tied to an ESOP-related offering, while continuing to advance its immunotherapy pipeline and collaboration with Kite Pharma. Fresh positive analyst coverage, highlighting Arcellx’s lead multiple myeloma candidate and its partnership with Kite Pharma, has drawn greater attention to the company’s approach to cell-based cancer treatments. Next, we’ll examine how this upbeat analyst...

Kinaxis Inc. has appointed Razat Gaurav as Chief Executive Officer, effective January 12, 2026, with Gaurav also joining the company’s Board of Directors, while interim CEO Bob Courteau returns to his role as non-executive Board Chair. Gaurav’s prior leadership in deploying advanced AI platforms and scaling global supply chain software businesses introduces a new emphasis on AI-driven supply chain orchestration at Kinaxis. Next, we’ll examine how Gaurav’s AI-focused supply chain background...

If you are wondering whether Arch Capital Group at around US$95 a share offers good value today, the key question is how its current price lines up with what the business may be worth. The stock has posted returns of 1.4% over the last 7 days, 3.7% over the last 30 days, 1.4% year to date, 5.6% over 1 year, 57.0% over 3 years and 188.5% over 5 years, which has put valuation firmly on many investors' radar. Recent attention on Arch Capital Group has been supported by ongoing coverage of the...

MMG (SEHK:1208) has moved ahead with a major expansion of its Khoemacau Copper Mine in Botswana, committing about US$900 million to increase output capacity and target lower operating costs. See our latest analysis for MMG. That expansion decision comes after a strong run in the stock, with a 30 day share price return of 11.71% and a 90 day share price return of 31.69%, alongside a very large 1 year total shareholder return that points to momentum still building rather than fading. If MMG’s...

MannKind Corporation recently released a business update outlining past progress and key upcoming regulatory milestones, including anticipated 2026 FDA decisions on an Afrezza label update, a supplemental Biologics License Application for pediatric use, and a supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, alongside advances in its inhaled therapy pipeline. A particularly important development is the alignment of multiple regulatory review timelines across Afrezza...

Leadership shakeup puts technology and regional focus in the spotlight Timken (TKR) is reworking its leadership chart, appointing a new chief technology officer and creating regional president roles. This move puts technology, AI and geographic execution more squarely in focus for shareholders. See our latest analysis for Timken. These leadership changes come after a strong run in the shares, with a 90 day share price return of 28.79% and a 1 year total shareholder return of 27.83%. This...

In recent days, FedEx has been highlighted for its pivot toward higher-value business-to-business shipping in sectors such as automotive, healthcare, and aerospace, supported by cost reduction efforts like DRIVE and Network 2.0 despite temporary operational headwinds. An interesting angle is how nearly half of FedEx’s latest quarterly revenue growth came from B2B customers, underlining the growing importance of these premium verticals for its global logistics model. We’ll now examine how...